Asia Pacific Monoclonal Antibodies Market size surpassed USD 34 billion in 2021 and is set to observe around 14.1% growth rate between 2022 and 2028.

Increasing focus of companies on discovery and development of novel mAb drugs to treat chronic and severe diseases will push the market growth. Growing support by government for the expansion of local drug development and manufacturing will benefit regional companies.

Get more details on this report - Request Free Sample PDF

The COVID-19 pandemic has had a positive impact on Asia Pacific monoclonal antibodies market growth. Growing demand of effective treatment options and targeted therapies to reduce the disease burden and patient mortality due to COVID-19 infection has propelled the market growth. Moreover, lack of treatment availability for COVID-19 has encouraged many companies to enter into R&D activities and drug development.

Asia Pacific Market, By Type

The fully human monoclonal antibodies segment dominated over 50% market share in 2021, attributed to advancement in mAb development technologies. The integration of genetic technologies into the human genome has yielded highly effective monoclonal antibodies. For instance, Humira, the highest selling fully human monoclonal antibody is based on phage display technology. Since the development of Humira, many companies such as Roche, and Merck have been involved in the development of fully human monoclonal antibody therapies. With increasing number of clinical and product approvals, the demand and usage for such mAbs is likely to grow exponentially, impelling the segmental growth.

Asia Pacific Market, By Application

Get more details on this report - Request Free Sample PDF

The oncology segment held around USD 13 billion revenue in 2021. The large revenue size is attributed to availability of number of monoclonal antibody drugs for the treatment of various type of drugs.

Some of the major oncology mAbs include Herceptin, Avastin, and Keytruda among others. Moreover, number of companies are currently working to develop novel mAbs for cancer treatment. Some of the companies with pipeline cancer drugs are Roche, GSK, CSL Behring, and AstraZeneca among others. Additionally, government funding for cancer research has also encouraged small market players and research institutes to develop and commercialize novel mAbs for cancer.

Asia Pacific Monoclonal Antibodies Market, By End-use

The hospitals segment will reach USD 37 billion revenue by 2028. Growing number of patient inflow in the hospital settings and capacity to serve larger patient pool are factors that drive the segment demand. Hospital settings offer higher accessibility of the advanced and novel therapeutic options for some of the chronic conditions such as cancer. Moreover, skilled medical specialists and variety of services under one roof also proves to be advantageous for the growth of hospital segment.

Asia Pacific Market, By Country

China monoclonal antibodies market accounted for more than 60% revenue share in 2021, owing to the growing adoption and availability of monoclonal antibody therapeutics in the country. Moreover, increasing R&D activity by various players for the development of novel mAb drugs in the region is likely to drive regional market expansion during the ongoing decade.

Competitive Industry Landscape

Prominent participants operating across the Asia Pacific monoclonal antibodies market include AbbVie Inc., F. Hoffmann-La Roche, Takeda Pharmaceuticals, Bristol Myers Squibb, Novartis AG, and Amgen. These companies are involved in strategic developments such as product launches, partnerships, collaborations with other players to improve their market customer base and market position.